About Regenus
Regeneus is an Australian biotechnology company aiming to improve the quality of life of patients suffering from pain.
We develop regenerative medicine products that interrupt the inflammatory cascade that leads to pain in the first place. Worldwide, there are hundreds of millions of patients suffering from short-term and chronic pain. Regeneus listed on the Australian Securities Exchange (ASX) in June 2013 under the ticker code ‘RGS’.
Investment highlight
Regeneus is focused on the US$69 billion global pain market, starting with commercialising Progenza for osteoarthritis in Japan
Latest news & insights
See below for the latest updates on the Company's activity.
Regeneus CEO Leo Lee with Proactive at the ASX Small and Mid-Cap Conference 2020
Regeneus CEO Leo Lee speaks to Proactive Investors' Andrew Scott while at the virtual ASX Small and Mid-Cap Conference 2020. During the interview, Leo talks about how Regeneus is working towards its mission to improve the quality of life for patients suffering from pain through their regenerative medicine products Progenza™ and Sygenus, the recent deal with Japanese manufacturing giant Kyocera Corporation, the experience of Regeneus' Board, and the current opportunity for investors.
Watch Leo's full interview with Proactive Investors here.
Mesenchymal Stem Cells: The Next Generation of Pain Treatments
Regeneus CEO Leo Lee is featured in the October 2020 edition of the European Pharmaceutical Review, writing on the field of regenerative medicine and its potential to dramatically transform the way that pain is treated.
Read Leo's full article in the European Pharmaceutical Review October 2020 digital edition here.
Regeneus featured in Morgans ‘Under The Microscope’ podcast
Morgans analyst Iain Wilkie sat down with Regeneus CEO Leo Lee to talk about the company's recent collaboration and licensing deal for Progenza OA for knee osteoarthritis in Japan and what it means for the company.
Listen to the podcast here.
Subscribe to our investor newsletter
Subscribe to Regeneus' investor newsletter for the latest information and updates